08.30
Welcome coffee
08.45
Welcome address, Philippe Métellus (FR)
09.00

Diagnostic approaches

Chair: A. Carpentier (FR) & M. Smits (NL)
  • 09.00 Molecular profiling to allocate patients to targeted clinical trials,J. M. Kros (NL)
  • 09.20 Brain Metastases,M. Westphal (DE)
  • 09.40 Leptomeningeal Metastases, E. Le Rhun (FR)
10.00

Immuno-oncology in CNS Metastases

Chair: F. A. S. Berghoff (AUT) & Dhermain (FR)
  • 10.00 Lessons from animal models, M. Valiente (SP)
  • 10.20 Overview: immunotherapy in CNS Metastases, M. Ahluwalia (US)
  • 10.40 Toxicity of immunotherapy in CNS Metastases, A. Carpentier (FR)
11.00
Coffee break and visit of the exhibition
11.20

Combined treatments for CNS Metastases

Chair: E. Moyal (FR) & Z. Ram (IS)
  • 11.20 Combination of immunotherapy and radiotherapy, F. Dhermain (FR)
  • 11.40 Combination of immunotherapy and other systemic pharmacotherapy, G. Finocchiaro (IT)
  • 12.00 Combination of other systemic pharmacotherapy and radiotherapy, U. Herrlinger (DE)
12.20

Keynote lecture

Chair: A. Carpentier (FR) & U. Herrlinger (DE)
  • 12.20 The future of radiotherapy for CNS Metastases: farewell to WBRT?A. Chalmers (UK)
12.50
Lunch
14.00

Comprehensive care of patients with Brain Metastases

Chair: G. Finocchiaro (IT) & E. Le Rhun (FR)
  • 14.00 Epilepsy in CNS Metastases: primary and secondary prevention,R. Rudà (IT)
  • 14.20 Maintaining cognitive function in patients with CNS Metastases receiving multimodality treatment, J-S.Wefel (US)
  • 14.40 Prevention and treatment of cerebro-vascular complications, C. Marosi (AUT)
  • 15.00 Efficacy, tolerability and safety of steroids in patients with CNS Metastases, P. Roth (CH)
15.20

Interactive case reports (progression/criteria of evaluation)

Chairs: P. Métellus (FR) & M. Weller (CH)
  • 15.20 Case 1 (Syst chemo), A. Darlix (FR)
  • 15.30 Case 2 (Immuno), A. S. Berghoff (AUT)
  • 15.40 Case 3 (RT), A. Modesto (FR)
15.50
Coffee break and visit of the exhibition
16.20

Keynote lecture

Chairs: M. Ahluwalia (US) & M. Westphal (DE)
  • 16.20 Assessing response and clinical benefit in clinical trials enrolling patients with Brain and leptomeningeal Metastases, M. Weller (CH)
  • 17.00 Activities of EORTC BTG CNS Metastases Committee, E. Le Rhun (FR)
  • 17.15 Guided poster walks
20.00
Gala dinner
Top